iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 12.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,866 shares of the company’s stock after buying an additional 1,508 shares during the quarter. SG Americas Securities LLC’s holdings in iTeos Therapeutics were worth $106,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its position in iTeos Therapeutics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after buying an additional 690 shares during the period. Creative Planning boosted its stake in shares of iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after acquiring an additional 1,196 shares in the last quarter. nVerses Capital LLC grew its holdings in shares of iTeos Therapeutics by 212.5% in the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after acquiring an additional 1,700 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new position in iTeos Therapeutics during the third quarter worth $31,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the transaction, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Wells Fargo & Company lowered their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Finally, Wedbush restated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Friday, January 10th.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS opened at $7.29 on Thursday. The firm has a market cap of $266.30 million, a P/E ratio of -2.31 and a beta of 1.38. iTeos Therapeutics, Inc. has a 1 year low of $7.06 and a 1 year high of $18.75. The firm’s 50 day moving average price is $7.71 and its 200 day moving average price is $10.48.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, equities analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.